Steven D. Singer, Partner, Wilmer Cutler Pickering Hale and Dorr


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Steven D. Singer, Partner, Wilmer Cutler Pickering Hale and Dorr

  1. 1. HPCGG Genetics Advisory Council Members Bios Russell Hirsch, MD, PhD, Managing Director, Prospect Venture Partners. Prior to establishing Prospect Venture Partners II, Russell was a member of the Health Care Technology Group at Mayfield. He joined Mayfield in 1992, served as a Venture Partner from 1993 to 1994 and as a General Partner from 1995-2000. Russell played a key role in Mayfield's investment activities in the biotechnology and medical device sectors. As an Associate, he participated actively in the incubation of Millennium Pharmaceuticals and as a General Partner he was responsible for the incubation of Intuitive Surgical Devices both of which are now publicly traded. (NASDAQ: MLNM), (NASDAQ:ISRG). Russell was at the University of California San Francisco from 1984-1992 where he was engaged in biomedical research. His work, published in a variety of respected journals, focused on important aspects of hepatitis B viral replication. His descriptions of the reverse transcription and packaging functions of polymerase gene products merited publication in Nature. Russell serves or has served on the Board of Directors of Intuitive Surgical (NASDAQ: ISRG), Sunesis, Valentis (NASDAQ: VLTS), Opus Medical, Orquest (NASDAQ: JNJ), Infinity Pharmaceuticals, Genpath, Hansen Medical and several other privately-held companies. Russell serves on the Boards of the Bay Area Bioscience Center and Interplast. Russell holds an M.D. and Ph.D. in Biochemistry from the University of California, San Francisco and a B.A. in Chemistry from the University of Chicago. Bill Helman, General Partners Greylock Bill joined Greylock in 1984. He is a graduate of Dartmouth College and the Harvard Business School. Bill represents Greylock on the boards of CentrePath, Incipient, iPhrase, netNumina, OATSystems, OutlookSoft, Reveal, Upromise, and Vettro. Bill also led Greylock's investments in Exact Sciences (EXAS), Tessera (merged with iXL), Ontogeny, Hyperion Software, Filene's Basement, Pharmacopeia (PCOP), Millennium Pharmaceuticals (MLNM), (acquired by Staples), and Vertex Pharmaceuticals (VRTX). John G. Freund, MD, Founding Partner Skyline Ventures John has been involved in founding, financing, managing and advising healthcare companies since 1982. He began his career at Morgan Stanley in New York, where he co-founded the Healthcare Group in the Corporate Finance Department and was later the original healthcare partner at Morgan Stanley Ventures. He then was an operating executive for six years as Executive Vice President of Acuson Corporation (an NYSE-traded company that is now part of Siemens), where he ran Marketing and led the cross-functional management of the company’s product introductions. In 1995, he licensed the technology that served as the core of Intuitive Surgical, Inc. (NASDAQ:ISRG), co-founded the company and raised its initial venture capital. He then spent two years as the West Coast partner at the Private Equity group of Chancellor Capital Management (now INVESCO), before founding Skyline in 1997. He has experience with most of the major sectors of the healthcare investment market including medical devices, information technology, small molecule chemistry and biochips, biotechnology and diagnostics. He received a B.A. from Harvard College, an M.D. from Harvard Medical School, and an M.B.A. from Harvard Business School, where he was a Baker Scholar and won the Loeb Fellowship in Finance. He was the co-author of The Official MBA Handbook, which spent 16 weeks on the New York Times bestseller list in 1982. 1
  2. 2. Stephen A. Sherwin, M.D., Chairman and Chief Executive Officer Dr. Sherwin, chairman of the board and chief executive officer, joined Cell Genesys in March 1990. Dr. Sherwin has served as chief executive officer since our inception and, in March 1994, was elected to the additional position of chairman of the board of directors. Dr. Sherwin also served as president until July 2001, at which time Dr. Vallner was appointed president. From 1983 to 1990, Dr. Sherwin held various positions at Genentech, Inc., a biotechnology company, most recently as vice president of clinical research. Prior to 1983, Dr. Sherwin was on the staff of the National Cancer Institute. Dr. Sherwin currently serves as the chairman of the board for Ceregene, Inc., a majority-owned subsidiary of Cell Genesys and a company that he co-founded in 2001. He was also a co-founder of Abgenix, Inc., a former subsidiary of Cell Genesys. Dr. Sherwin currently serves as member of the board of directors for Neurocrine Biosciences, Inc. and Rigel Pharmaceuticals, Inc. and also serves as a board member of the Biotechnology Industry Organization. He holds a B.A. in biology from Yale University and an M.D. from Harvard Medical School and is board-certified in internal medicine and medical oncology James N. Topper, M.D., Ph.D., Venture Partner, Frazier Healthcare Dr. Topper works primarily on seed/early stage biotech investment opportunities. Prior to joining Frazier Healthcare in August 2003, he served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Prior to the merger of COR and Millennium, Dr. Topper served as the Vice President of Biology at COR, and was responsible for managing all of its research activities. He served on the faculties of Stanford Medical School and Harvard Medical School prior to joining COR, where he functioned as a clinician, instructor and basic investigator. Dr. Topper received his M.D. and Ph.D. (in Biophysics) from Stanford University School of Medicine in 1991 under the auspices of the Medical Scientist Training Program. He completed his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women's Hospital in Boston and is board certified in both disciplines. After completing a research fellowship in the Vascular Research Division in the department of Pathology at the Brigham and Women's hospital, he joined the faculty of Harvard Medical School from 1997-1998, and subsequently Stanford University as an Assistant Professor of Medicine (Cardiovascular) in July 1998. He has authored over 50 publications, and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford University. He continues to hold an appointment as a Clinical Assistant Professor of Medicine at Stanford University and as a Cardiology Consultant to the Palo Alto Veterans Administration Hospital. Dr. Topper currently serves as an observer on the boards of CoTherix, Inc., and Portola Pharmaceuticals. Norman C. Selby, Chairman, Windhover Information, Inc. Mr. Selby is currently the Chairman of Windhover Information, Inc., a publishing and information company in the pharmaceutical, biotechnology and medical products industries. Prior to that, Mr. Selby served as the president and chief executive officer of TransForm Pharmaceuticals, Inc. Previously, he served as the head of Consumer Internet Business at Citigroup/Citicorp. Also, Mr. Selby was head of the global pharmaceuticals practice at McKinsey & Company, the international management consulting firm, and the interim chief operating officer of the New York Blood Center. Currently, he is also on the board of Transform Pharmaceuticals, Inc., Medsite, Inc. and the Memorial Sloan-Kettering Cancer Center. Mr. Selby holds a bachelor's degree in architecture from Yale College, and he received his MBA from the Harvard Graduate School of Business Administration. 2
  3. 3. A. Grant Heidrich, III, Partner Emeritus, Mayfield Mr. Heidrich is a partner at Mayfield, a California-based venture capital firm focused on early- stage technology companies. Previously, he served as vice president of Wood River Capital, a New York City-based venture capital firm. Currently, Mr. Heidrich serves on the board of directors at a number Grant has served as President of the Western Association of Venture Capital and is a former board member of the National Venture Capital Association. He earned a Bachelor's degree in human biology from Stanford University and an M.B.A. from Columbia University. Robert Tepper, M.D., President, Research and Development, Millennium Pharmaceuticals Dr. Tepper has served as chief scientific officer at Millennium since March 1999. He joined Millennium in August 1994 as director of biology and became vice president, biology in January 1996. From 1990 to 1994, Dr. Tepper served as director of the laboratory of tumor biology at Massachusetts General Hospital Cancer Center where he was the recipient of the Lucille P. Markey Biomedical Scholar award. Dr. Tepper is also a founder and former member of the scientific advisory board of Cell Genesys, Inc. He currently serves as a member of the National Advisory Council for Human Genome Research. Dr. Tepper received his M.D. from Harvard Medical School and completed his residency in medicine at Massachusetts General Hospital, where he was chief resident. He continues to serve as an adjunct faculty member of Harvard Medical School and the Massachusetts General Hospital and as a member of the Board of Associates of the Whitehead Institute for Biomedical Research. Jeff Elton,Principal, McKinsey & Company Jeff Elton, Ph.D. is a principal in McKinsey & Company's Boston Office. Dr. Elton focuses on technology-intensive industries, including biotechnology, pharmaceuticals, health and bioinfomatics and medical devices. He is a leader of the Firm's Product Development and Pharmaceutical and Medical Products Practices. Jeff is on the Board of Directors of the Elizabeth Glaser Pediatric AIDS Foundation Michael Schmertzler Managing Director of Aries Advisors, LLC, Michael is a sub-advisor to Credit Suisse First Boston Equity Partners, LLC and its affiliates, and the Chair of the Investment Committee of those funds. Mr. Schmertzler is an Adjunct Professor at Yale University. Prior to Aries, Mr. Schmertzler was Co-Head of U.S. and Canadian Private Equity at Credit Suisse First Boston. Prior to Credit Suisse First Boston, Mr. Schmertzler was the President of the Morgan Stanley Leveraged Capital Funds and Morgan Stanley Leveraged Equity Fund II, as well as a Managing Director in that firm’s mergers and acquisitions and corporate finance departments. Mr. Schmertzler had previously been the Head of International Investment Banking and International Institutional Sales and Trading at Shearson Lehman American Express and a member of that firm’s Board of Directors. Prior to that, he was Chief Financial Officer, a Managing Director, and an investment banker at Lehman Brothers Kuhn Loeb Incorporated. Mr. Schmertzler currently serves on the boards of Idenix Pharmaceuticals, PTC Therapeutics, Segway, Triad Therapeutics and Zyomyx; he is a designated board observer at Sunesis Pharmaceuticals and is a Trustee of the National Outdoor Leadership School. Mr. Schmertzler received his B.A. from Yale College in Molecular Biophysics and Biochemistry, History, and City Planning. He attended the Woodrow Wilson School at Princeton University and received an M.B.A. from the Harvard Business School 3
  4. 4. Marcia A. Kean, Chief Executive Officer, Feinstein Kean Healthcare Marcia Kean has close to 30 years of health care industry experience, including senior positions with pharmaceutical, biotechnology and medical service firms, non-profit research organizations, and consulting firms. Marcia has been a prominent author and speaker on key communications and valuation issues facing senior management. Prior to her recent appointment as Chief Executive Officer of Feinstein Kean Healthcare, she was SVP-Commercialization at Ardais Corporation, a privately held clinical genomics firm. Mrs. Kean served as founder and Managing Director of the Corporate Communications practice at Feinstein Kean Healthcare. In that role, she led a full-service U.S. and international corporate communications practice, with specialization in the definition and repositioning of corporate identities; planning and fulfillment of valuation potential; investor relations and media strategy and execution; and management of sensitive or challenging corporate issues. From 1982 to 1990, Mrs. Kean served simultaneously as vice president, corporate communications of Damon Corporation (NYSE) and of its subsidiary, Damon Biotech (Nasdaq). Mrs. Kean holds an M.B.A. in finance from New York University and a B.A. from the University of California at Berkeley. Steven D. Singer, Partner, Wilmer Cutler Pickering Hale and Dorr Mr. Singer is Co-Chair, Life Sciences Group; Vice Chair, Corporate Department and practices general corporate law, and primarily represents biotechnology and biomedical companies. Mr. Singer has extensive experience in corporate partnering and joint venture and licensing agreements. He has worked on a wide range of corporate transactions, including public and private securities offerings, mergers and acquisitions, research and development agreements, joint ventures, license agreements, and other major and minor corporate work. Mr. Singer is a member of the American Bar Association, the Massachusetts Biotechnology Council and the Biotechnology Industry Organization. Mr. Singer received a J.D. degree, magna cum laude, from Harvard Law School, where he was a member of the Harvard Law Review. He graduated summa cum laude from Tufts University 4